Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease

NCT02630316 is registered in ClinicalTrials.gov with United Therapeutics as lead sponsor.

NCT NCT02630316
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02630316 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
Lead sponsor
United Therapeutics
Phase
Phase 2/3
Overall status
Completed
Start date
February 3, 2017
Completion date
December 26, 2019
Enrollment
326 (actual)
Sites
97

Conditions

As the registry lists them; a condition with its own page is linked.

combined pulmonary fibrosis and emphysema, interstitial lung disease, pulmonary hypertension